Type 2 Diabetes Study Seeks Volunteers taking NPH, Lantus or Basaglar (U100 or U300), Levemir, or Tresiba (U100 or U200). Participants CANNOT be taking Bolus (Short-Acting) Insulin.


We are currently seeking volunteers who are diagnosed with Type 2 Diabetes and who are treating with Basal Insulin, with or without up to 2 other oral diabetes medications for the past 3 months:

  • Once or Twice Daily: NPH, Lantus or Basaglar (U100 or U300), Levemir, Tresiba (U100 or U200).
  • With or without up to 2 of the following:
    • Stable dose Metformin ³ 1500mg QD; 
    • SUs: Glimepiride, Glipizide, Glyburide;
    • DPP-4’s: Januvia, Onglyza, Tradjenta, Nesina.


This is a study of an investigational once weekly injectable medication that may help to improve blood sugar levels and help lose weight. All participants will switch to taking Lantus (Glargine-U100) insulin, and will be assigned to one of four groups: three of every four of the participants will add on the investigational once weekly injectable medication, and one of every four will add on (FDA Approved) Daily Insulin Humalog (Lispro-U100) to be administered three times a day. Participants taking Metformin can continue taking their Metformin.

Participants must be willing to keep a paper glucose diary and be willing to perform ten 7-point glucose profiles during the study (10 times during the study where you check your blood sugars at 7 specific time points.) Participants will also receive a dilated Fundoscopic exam to test for retinopathy and macular edema.

Please contact us for further details by filling out this volunteer form below or calling us at 1-888-478-8343.